Bisphophonates to prevent skeletal morbidity in patients with lung cancer with bone metastases

Clinical Lung Cancer

Volumn 5, Issue 5, 2004, Pages 267-269

  Price, Nancy ^a   Belani, Chandra P ^a   Jain, Vinay K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM DERIVATIVE; CLODRONIC ACID; DOCETAXEL; GEMCITABINE; HYDROXYAPATITE; PAMIDRONIC ACID; PHOSPHONIC ACID DERIVATIVE; PLACEBO; VITAMIN D; ZOLEDRONIC ACID; IMIDAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DISEASE; BONE METASTASIS; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERCALCEMIA; LUNG CANCER; SIDE EFFECT; STATISTICAL SIGNIFICANCE; BONE TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; MORBIDITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SMALL CELL CARCINOMA;

BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORBIDITY; PROGNOSIS;

EID: 2442428615     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-7304(11)70347-3     Document Type: Article

References (14)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80:1588-1594.
2. Tchekmedyian S, Rosen LS, Gordon D., et al. Long-term efficacy and safety of zoledronic acid in reducing skeletal complications in patients with bone metastases from solid tumors. Proc Am Soc Clin Oncol 2003; 22:630 (Abstract #2532).
3. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
4. Rosen LS, Gordon DH, Dugan W, Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100:36-43.
5. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735-1744.
6. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91:1191-1200.
7. Dunford JE, Thompson K, Coxon FP et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296:235-242.
8. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302:1055-1061.
9. Pickering LM, Mansi JL, Colston KW, et al. Adhesion of breast cancer cells to extracellular matrices is inhibited by zoledronic acid and enhanced by aberrant Ras signalling. Proc Amer Soc Clin Oncol 2003; 22:863 (Abstract #3468).
10. Valleala H, Hanemaaijer R, Mandelin J, et al. Regulation of MMP-9 (gelatinase B) in activated human monocyte/macrophages by two different types of bisphosphonates. Life Sci 2003; 73:2413-2420.
11. Jagdev SP, Coleman RE, Shipman CM, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84:1126-1134.
12. Ullen AL, Lennartsson M, Hjelm-Eriksson M, et al. Additive/synergistic anti-tumoral effects on prostate cancer cells in vitro following treatment with a combination of gemcitabine and zoledronic acid. Proc Am Soc Clin Oncol 2003; 22:432 (Abstract #1737).
13. Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20(suppl 2):45-54.
14. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21:3150-3157.